• 1
    Haferlach T, Bacher U, Kohlmann A et al. Discussion of the applicability of microarrays: Profiling of leukemias. Methods Mol Biol 2009; 509: 1533.
  • 2
    Ross ME, Mahfouz R, Onciu M et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood 2004; 104: 36793687.
  • 3
    Ross ME, Zhou X, Song G et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003; 102: 29512959.
  • 4
    Wouters BJ, Lowenberg B, Delwel R. A decade of genome-wide gene expression profiling in acute myeloid leukemia: Flashback and prospects. Blood 2009; 113: 291298.
  • 5
    Yeoh EJ, Ross ME, Shurtleff SA et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1: 133143.
  • 6
    Kohlmann A, Grossmann V, Haferlach T. Integration of next-generation sequencing into clinical practice: Are we there yet? Semin Oncol 2012; 39: 2636.
  • 7
    Lamb J, Crawford ED, Peck D et al. The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 19291935.
  • 8
    Zhang SD, Gant TW. sscMap: An extensible Java application for connecting small-molecule drugs using gene-expression signatures. Bmc Bioinformatics 2009; 10: 236.
  • 9
    McArt DG, Zhang SD. Identification of candidate small-molecule therapeutics to cancer by gene-signature perturbation in connectivity mapping. Plos One 2011; 6: e16382.
  • 10
    Zuber J, Radtke I, Pardee TS et al. Mouse models of human AML accurately predict chemotherapy response. Genes Dev 2009; 23: 877889.
  • 11
    Zeisig BB, Garcia-Cuellar MP, Winkler TH et al. The oncoprotein MLL-ENL disturbs hematopoietic lineage determination and transforms a biphenotypic lymphoid/myeloid cell. Oncogene 2003; 22: 16291637.
  • 12
    Cuenco GM, Nucifora G, Ren R. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: A model for human AML. Proc Natl Acad Sci USA 2000; 97: 17601765.
  • 13
    Cuenco GM, Ren R. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia. Oncogene 2001; 20: 82368248.
  • 14
    Argiropoulos B, Humphries RK. Hox genes in hematopoiesis and leukemogenesis. Oncogene 2007; 26: 67666776.
  • 15
    Lawrence HJ, Rozenfeld S, Cruz C et al. Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias. Leukemia 1999; 13: 19931999.
  • 16
    Soulier J, Clappier E, Cayuela JM et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood 2005; 106: 274286.
  • 17
    Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531537.
  • 18
    Armstrong SA, Staunton JE, Silverman LB et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30: 4147.
  • 19
    Ferrando AA, Armstrong SA, Neuberg DS et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: Dominance of HOX dysregulation. Blood 2003; 102: 262268.
  • 20
    So CW, Karsunky H, Wong P et al. Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9. Blood 2004; 103: 31923199.
  • 21
    Somervaille TC, Matheny CJ, Spencer GJ et al. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 2009; 4: 129140.
  • 22
    Wong P, Iwasaki M, Somervaille TC et al. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev 2007; 21: 27622774.
  • 23
    Faber J, Krivtsov AV, Stubbs MC et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 2009; 113: 23752385.
  • 24
    Haferlach C, Mecucci C, Schnittger S et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood 2009; 114: 302432.
  • 25
    Kroon E, Krosl J, Thorsteinsdottir U et al. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J 1998; 17: 37143725.
  • 26
    Wilhelm BT, Briau M, Austin P et al. RNA-seq analysis of 2 closely related leukemia clones that differ in their self-renewal capacity. Blood 2011; 117: e2738.
  • 27
    Haferlach T, Kohlmann A, Wieczorek L et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: Report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 2010; 28: 25292537.
  • 28
    Thorsteinsdottir U, Mamo A, Kroon E et al. Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood 2002; 99: 121129.
  • 29
    Bijl J, Sauvageau M, Thompson A et al. High incidence of proviral integrations in the Hoxa locus in a new model of E2a-PBX1-induced B-cell leukemia. Genes Dev 2005; 19: 224233.
  • 30
    Thompson A, Quinn MF, Grimwade D et al. Global down-regulation of HOX gene expression in PML-RARalpha + acute promyelocytic leukemia identified by small-array real-time PCR. Blood 2003; 101: 15581565.
  • 31
    Hu E, Dul E, Sung CM et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 2003: 720728.
  • 32
    Ocio EM, Vilanova D, Atadja P et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica 2010; 95: 794803.
  • 33
    Srivastava RK, Kurzrock R, Shankar S. MS- 275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial–mesenchymal transition in vivo. Mol Cancer Ther 2010; 9: 32543266.
  • 34
    Hooker JM, Kim SW, Alexoff D et al. Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: Pk studies of [C]MS-275 using positron emission tomography. ACS Chem Neurosci 2010; 1: 6573.
  • 35
    Standeven AM, Johnson AT, Escobar M et al. Specific antagonist of retinoid toxicity in mice. Toxicol Appl Pharmacol 1996; 138: 169175.
  • 36
    Schwind S, Marcucci G, Maharry K et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. Blood 2010; 116: 56605669.
  • 37
    Becker H, Marcucci G, Maharry K et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: A Cancer and Leukemia Group B study. J Clin Oncol 2010; 28: 596604.
  • 38
    Muntean AG, Hess JL. The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol 2012; 7: 283301.
  • 39
    Huang Y, Sitwala K, Bronstein J et al. Identification and characterization of Hoxa9 binding sites in hematopoietic cells. Blood 2012; 119: 388398.
  • 40
    Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003; 63: 36373645.
  • 41
    Scandura JM, Roboz GJ, Moh M et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood 2011; 118: 14721480.
  • 42
    Dassé E, Volpe G, Walton DS et al. Distinct regulation of c-myb gene expression by HoxA9, Meis1 and Pbx proteins in normal hematopoietic progenitors and transformed myeloid cells. Blood Cancer J. 2012; 2: e76.
  • 43
    Stumpel DJ, Schneider P, Seslija L et al. Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia. Leukemia 2012; 26: 682692.
  • 44
    Daigle SR, Olhava EJ, Therkelsen CA et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011; 20: 5365.
  • 45
    Huang Y, Sitwala K, Bronstein J et al. Identification and characterization of Hoxa9 binding sites in hematopoietic cells. Blood 2012: 12; 119: 38898.
  • 46
    Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27: 54595468.
  • 47
    Bhatla T, Wang J, Morrison DJ et al. Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood 2012; 119: 52015210.
  • 48
    Glauben R, Sonnenberg E, Zeitz, et al. HDAC inhibitors in models of inflammation-related tumorigenesis. Cancer Lett 2009; 280: 154159.